Hermetica Superfood Encyclopedia
The Short Answer
Banisteriopsis laevis is presumed to contain β-carboline alkaloids — most notably harmine — which act as reversible monoamine oxidase A (MAO-A) inhibitors, potentiating serotonergic and dopaminergic neurotransmission. Ethnobotanical documentation among Shipibo-Conibo healers identifies this vine as an ayahuasca admixture plant, though species-specific phytochemical and clinical data remain extremely limited in the peer-reviewed literature.
CategoryHerb
GroupAmazonian
Evidence LevelPreliminary
Primary KeywordBanisteriopsis laevis cumandu ba
Cumandu ba — botanical close-up
Health Benefits
**MAO-A Inhibition (Inferred)**
Harmine-class alkaloids characteristic of the Banisteriopsis genus reversibly inhibit monoamine oxidase A, increasing synaptic availability of serotonin, dopamine, and norepinephrine; this mechanism underlies the genus's traditional use in mood and consciousness modulation.
**Ceremonial and Psychospiritual Use**
Among Shipibo-Conibo practitioners, cumandu ba is integrated into ayahuasca ceremony as an additive or substitute vine, used to deepen visionary states and facilitate therapeutic healing rituals reported across multiple ethnobotanical surveys.
**Potential Anti-inflammatory Activity**: Research on closely related B
caapi extracts demonstrated reduction of pro-inflammatory cytokines including IL-2, IL-6, IL-17, and TNF-α in microglial cell models, suggesting shared anti-neuroinflammatory potential warranting direct investigation in B. laevis.
**Anticholinesterase Properties (Genus-Level)**
Species within the Banisteriopsis genus have demonstrated acetylcholinesterase inhibitory activity in in vitro assays, a mechanism relevant to neuroprotection and cognitive function, though this has not been confirmed specifically for B. laevis.
**Anxiolytic Potential (Preclinical Inference)**
Harmine, identified in multiple Banisteriopsis species, has demonstrated anxiolytic effects in rodent models at doses of 5–15 mg/kg via GABAergic and serotonergic modulation; whether B. laevis alkaloid concentrations achieve comparable effects is undocumented.
**Antimicrobial Activity (Genus-Level)**
Broad-spectrum phytochemical screening of Banisteriopsis spp. has identified flavonoids and tannins with antimicrobial properties against bacterial and fungal pathogens in vitro, though species-specific minimum inhibitory concentration data for B. laevis are absent from the literature.
Origin & History
Natural habitat
Banisteriopsis laevis is a woody liana native to the Amazonian basin, distributed across tropical South America including Peru, Brazil, and Colombia, where it thrives in humid lowland rainforest and riverine gallery forest environments. The plant belongs to the family Malpighiaceae and grows as a climbing vine in dense canopy ecosystems, often alongside its better-studied congener Banisteriopsis caapi. In Shipibo-Conibo indigenous communities of the Peruvian Amazon, it is recognized as a distinct botanical entity used in ceremonial and medicinal contexts, sometimes incorporated into or alongside ayahuasca preparations.
“Among the Shipibo-Conibo people of the Ucayali River basin in Peru, cumandu ba (Banisteriopsis laevis) is recognized as a distinct plant ally within the complex taxonomy of ayahuasca-related vines, a knowledge system that distinguishes dozens of Banisteriopsis morphotypes by vine color, leaf texture, habitat, and ceremonial purpose. Shipibo cosmology frames these plants as teachers or 'plant doctors' (doctores), each carrying specific healing and visionary properties communicated through icaros (healing songs) learned during maestro apprenticeship periods that may last years or decades. The broader genus Banisteriopsis has been documented in Amazonian ceremonial use for at least several centuries, with colonial-era Jesuit records from the 17th century describing vine-based intoxicating brews among Andean and Amazonian peoples. The species-level distinction of B. laevis within Shipibo practice reflects sophisticated indigenous botanical classification systems that predate and frequently surpass Western taxonomic documentation of intrageneric diversity.”Traditional Medicine
Scientific Research
Peer-reviewed literature specific to Banisteriopsis laevis as a distinct species is essentially absent from major scientific databases including PubMed, Web of Science, and Scopus as of the knowledge cutoff, representing a significant gap in Amazonian ethnopharmacology. The broader body of evidence for the Banisteriopsis genus derives overwhelmingly from studies on B. caapi, including in vitro cytokine assays, rodent behavioral pharmacology models, and a growing number of small human observational and clinical studies focused on ayahuasca brew preparations of undetermined botanical composition. Ethnobotanical documentation of B. laevis by name appears primarily in indigenous plant inventories and anthropological fieldwork among Shipibo-Conibo communities, not in controlled pharmacological investigations. The evidence base for this specific taxon must therefore be classified as preliminary and largely inferential, extrapolated from congener research rather than direct experimental data.
Preparation & Dosage
Traditional preparation
**Traditional Ayahuasca Decoction**
Bark and stems of B. laevis are prepared by Shipibo-Conibo healers through prolonged aqueous decoction (4–12 hours) combined with Psychotria viridis or other DMT-containing admixture plants; exact vine-to-water ratios are ceremony-specific and knowledge held by trained curanderos.
**Vine Segment Use**
In traditional preparation, woody stem sections approximately 30–100 cm in length are macerated, scraped, or pounded to expose the cambium layer before boiling, maximizing alkaloid extraction into the aqueous phase.
**No Standardized Supplement Form**
As of current knowledge, no commercially standardized extract, capsule, or tincture of B. laevis specifically is available; products labeled 'Banisteriopsis' almost exclusively refer to B. caapi.
**Alkaloid Dosing Reference (Genus-Level)**
1–3 mg/kg body weight of total β-carbolines; specific alkaloid concentrations in B
Effective harmine dosing in human ayahuasca contexts is estimated at . laevis stem bark have not been published.
**Timing and Set/Setting**
Traditional consumption occurs in structured overnight ceremonial contexts under curandero supervision; no clinical dosing schedule has been established for B. laevis as a standalone ingredient.
Nutritional Profile
Banisteriopsis laevis is not consumed as a food and has no meaningful macronutrient profile relevant to nutrition. Primary phytochemicals of interest — inferred from genus-level analysis — include β-carboline alkaloids (harmine, harmaline, tetrahydroharmine) concentrated in stem bark tissue, with reported concentrations in B. caapi bark ranging from 0.2–2.0% dry weight for total alkaloids depending on ecotype and harvest season. Flavonoid glycosides and phenolic acids (including proanthocyanidins and caffeic acid derivatives) have been detected in Banisteriopsis spp. via HPLC analysis and may contribute antioxidant activity. Tannins are present in the woody tissue and may reduce gastrointestinal absorption of alkaloids, a bioavailability factor relevant to traditional preparation methods that involve long decoction times and acidic aqueous extraction environments. No proximate nutritional analysis of B. laevis specifically has been published.
How It Works
Mechanism of Action
Based on genus-level phytochemistry, cumandu ba is presumed to exert primary pharmacological activity through β-carboline alkaloids — particularly harmine and potentially harmaline — that competitively and reversibly inhibit monoamine oxidase A (MAO-A) at the flavin adenine dinucleotide (FAD) binding site, preventing oxidative deamination of serotonin, dopamine, and tryptamine derivatives. Harmine also functions as a potent inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), which modulates neurogenesis, tau phosphorylation, and NFATc transcription factor activity relevant to neuroinflammation. Secondary phytochemicals including flavonoids may contribute to cyclooxygenase inhibition and free radical scavenging, complementing the alkaloid-driven central nervous system effects. The oral psychoactivity of N,N-DMT-containing brew components is critically dependent on MAO-A inhibition provided by β-carbolines, which is the primary mechanistic rationale for B. laevis inclusion in ayahuasca preparations by traditional Shipibo practitioners.
Clinical Evidence
No clinical trials have been conducted specifically using Banisteriopsis laevis as an isolated intervention or characterized extract. Human evidence for pharmacologically related compounds is drawn from ayahuasca research, including a randomized placebo-controlled crossover trial (n=29) published in Psychological Medicine (2019) demonstrating acute reductions in depressive symptom scores (MADRS) following a single ayahuasca dose, though brew botanical composition varied between studies. A naturalistic observational study by Bouso et al. (2012) assessed long-term ayahuasca users (n=127) and found no evidence of cognitive impairment and some measures of improved psychological wellbeing, but the specific alkaloid contributions of B. laevis versus other vine constituents cannot be isolated. Confidence in attributing any specific clinical effect to B. laevis independently is very low; the plant should be understood as one component within a complex multi-species preparation whose total pharmacology has not been disaggregated.
Safety & Interactions
Banisteriopsis laevis carries no species-specific clinical safety data; risk assessment must be extrapolated from the broader MAO-A inhibitor pharmacology established for B. caapi and synthesized harmine. As a presumptive MAO-A inhibitor, B. laevis preparations pose serious risk of hypertensive crisis ('cheese reaction') when combined with tyramine-rich foods (aged cheeses, cured meats, fermented products) and represent a pharmacokinetic contraindication with serotonergic drugs including SSRIs, SNRIs, tricyclics, lithium, and tramadol due to risk of serotonin syndrome. Concurrent use with sympathomimetic agents (amphetamines, cocaine, MDMA), other MAOIs, or CYP2D6 substrates is contraindicated. Use during pregnancy and lactation is contraindicated given the vasoactive and potentially uterotonic properties of β-carbolines and the absence of safety data; individuals with cardiovascular disease, uncontrolled hypertension, epilepsy, or psychotic spectrum disorders should avoid all preparations containing this or related species.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Banisteriopsis laevisCumandu baShipibo ayahuasca vineMalpighiaceae lianacaapi variant
Frequently Asked Questions
What is cumandu ba and how is it used in ayahuasca?
Cumandu ba (Banisteriopsis laevis) is a woody Amazonian vine used by Shipibo-Conibo healers as a component or variant vine in ayahuasca preparations, where its stem bark is boiled in long aqueous decoctions. Like its congener B. caapi, it is believed to supply β-carboline alkaloids including harmine that inhibit monoamine oxidase A, allowing DMT from admixture plants such as Psychotria viridis to remain orally active. It is distinguished from B. caapi by Shipibo taxonomists based on morphological features and attributed ceremonial properties.
Does Banisteriopsis laevis contain harmine?
Banisteriopsis laevis has not been subject to published phytochemical analysis confirming specific alkaloid content, though its classification within the Banisteriopsis genus and its traditional use as an ayahuasca vine strongly suggest the presence of harmine and related β-carboline alkaloids. In the well-studied congener B. caapi, total alkaloid content in stem bark ranges from approximately 0.2 to 2.0% dry weight, with harmine typically representing the dominant fraction. Direct quantification of harmine in B. laevis tissue requires chromatographic analysis not yet documented in the peer-reviewed literature.
Is cumandu ba the same as Banisteriopsis caapi?
No — cumandu ba (Banisteriopsis laevis) and Banisteriopsis caapi are distinct species within the same genus, though both are used in Amazonian ayahuasca traditions and likely share pharmacologically relevant β-carboline alkaloid chemistry. Shipibo-Conibo healers explicitly distinguish between multiple Banisteriopsis morphotypes, assigning different ceremonial roles, harvesting seasons, and healing properties to each. B. caapi is far more extensively documented in Western pharmacological and clinical literature; B. laevis remains largely unstudied as a separate taxon.
What are the risks and drug interactions of cumandu ba?
As a presumptive MAO-A inhibitor, cumandu ba preparations are contraindicated with serotonergic medications (SSRIs, SNRIs, MAOIs, tramadol) due to serotonin syndrome risk, and with tyramine-rich foods due to risk of acute hypertensive crisis. Concurrent use with sympathomimetic substances including amphetamines, MDMA, or cocaine is dangerous and potentially fatal. There are no established safe doses outside traditional ceremonial contexts, and the complete interaction profile cannot be defined given the absence of clinical pharmacokinetic data specific to this species.
How much scientific evidence exists for Banisteriopsis laevis health benefits?
Direct scientific evidence for Banisteriopsis laevis specifically is essentially absent from the peer-reviewed literature, with no published pharmacological studies, clinical trials, or standardized phytochemical analyses identified for this species. Available evidence is limited to ethnobotanical documentation of its traditional use among Shipibo-Conibo communities and genus-level pharmacology extrapolated from B. caapi research. Any health benefit claims must therefore be considered unvalidated and preliminary; researchers interested in this species would need to conduct original phytochemical characterization before any clinical claims could be substantiated.
How does cumandu ba differ from other Banisteriopsis species used in traditional medicine?
Banisteriopsis laevis (cumandu ba) is distinguished from B. caapi primarily by its botanical morphology and alkaloid profile, though both contain harmine-class compounds. Cumandu ba is traditionally preferred by certain Amazonian groups like the Shipibo-Conibo for specific ceremonial applications, and some ethnobotanical sources suggest it may have a different ratio of alkaloids compared to caapi, potentially affecting its pharmacological potency. However, direct comparative phytochemical analyses between these species remain limited in published literature.
What is the bioavailability difference between fresh and dried cumandu ba preparations?
Fresh cumandu ba vine contains higher moisture content and potentially more volatile alkaloid compounds, while drying concentrates the remaining alkaloids but may degrade some heat-sensitive constituents through oxidation. The traditional preparation method—typically as a decocted brew—extracts harmine and related alkaloids into the aqueous phase, with bioavailability influenced by brewing duration, water temperature, and whether the material is fresh or aged. Dried and powdered forms tend to have more consistent alkaloid concentration than fresh material, making dosing more predictable in practice.
Are there specific populations for whom cumandu ba use is contraindicated beyond standard drug interactions?
Cumandu ba should be avoided by individuals with uncontrolled hypertension, cardiac arrhythmias, or a personal or family history of serotonin syndrome risk factors, given its MAO-A inhibitory mechanism and monoamine-elevating effects. Individuals with severe psychiatric conditions (particularly untreated psychosis or bipolar disorder) and those taking conventional antidepressants or stimulants face elevated risk of adverse interactions. Pregnant and nursing individuals should avoid use due to the lack of safety data and the herb's potent neurochemical effects on developing fetal and neonatal nervous systems.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w cumandu-ba-banisteriopsis-laevis curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
